Market Cap 20.53B
Revenue (ttm) 2.88B
Net Income (ttm) 1.20B
EPS (ttm) N/A
PE Ratio 18.28
Forward PE 17.37
Profit Margin 41.53%
Debt to Equity Ratio 0.00
Volume 209,304
Avg Vol 443,700
Day's Range N/A - N/A
Shares Out 43.06M
Stochastic %K 13%
Beta 0.84
Analysts Strong Sell
Price Target $536.75

Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to d...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 301 608 9292
Address:
1000 Spring Street, Silver Spring, United States
cubie
cubie Jan. 14 at 11:40 PM
$LQDA $UTHR when patent ruling, asking for some friends😅
1 · Reply
watchfilingdocuments
watchfilingdocuments Jan. 13 at 11:11 PM
$DDD Updates from Needham Growth Conference, Part 4 of 8: Capable of 3d printing a full human lung. Partnered with all the internal complexity that the body needs. United Therapeutics ($UTHR ) cellularizes it to turn it into a full working lung. In a few years, we'll see humans walking around with a fully 3d printed lung in their body. Webcast: https://wsw.com/webcast/needham148/ddd/2028852
0 · Reply
Outcomes
Outcomes Jan. 13 at 2:06 PM
0 · Reply
Quantumup
Quantumup Jan. 13 at 1:57 PM
BTIG reiterated $LQDA Buy/$49 $UTHR $JNJ $MRK $INSM Here's what BTIG said: https://x.com/Quantumup1/status/2011073992057139619?s=20
0 · Reply
Michaelluh
Michaelluh Jan. 13 at 1:46 PM
$MNKD $UTHR “We have been building up our inventory of Tyvaso inhalers so that we have an adequate supply of drugs and devices to stay on top of literally a hockey stick launch into the IPF indication.” - Martine Rothblatt
0 · Reply
Affizle
Affizle Jan. 12 at 10:45 PM
$MNKD Sounds like $UTHR's CEO is about to neuter Mannkind when it dumps Mannkind's inhaler for their own! Now you know why United has no interest in buying Mannkind! lolz!
2 · Reply
VJLer
VJLer Jan. 12 at 9:52 PM
$DDD $UTHR i wsnt able to here webcast. But i could see the presentation doc.
0 · Reply
VJLer
VJLer Jan. 12 at 9:39 PM
$DDD $UTHR presentation is about to start from JPM. You are able to see a slide on autologous regenerative medicine for creating unlimited supply of transplantable organs.
1 · Reply
clan
clan Jan. 11 at 2:20 AM
$MNKD 2026 for Mannkind Corp. and MNKD will be transfomational; an inflection point. #ItsGrowTime #StockAppreciation $UTHR $SCPH
0 · Reply
clan
clan Jan. 10 at 11:30 PM
$MNKD $UTHR $MRK #inhalablemedications #inhalemyinsulin #afrezza #tyvaso #technosphere #moneymaker #goldengoose
0 · Reply
Latest News on UTHR
Flurry of Bullish Inflows Sends United Therapeutics Higher

Dec 3, 2025, 7:19 AM EST - 6 weeks ago

Flurry of Bullish Inflows Sends United Therapeutics Higher


United Therapeutics Corporation - Special Call

Sep 28, 2025, 5:27 PM EDT - 3 months ago

United Therapeutics Corporation - Special Call


United Therapeutics: Is UTHR Stock Still A Buy At $400?

Sep 3, 2025, 10:10 AM EDT - 4 months ago

United Therapeutics: Is UTHR Stock Still A Buy At $400?


Why Is United Therapeutics Stock Rallying On Tuesday?

Sep 2, 2025, 10:59 AM EDT - 4 months ago

Why Is United Therapeutics Stock Rallying On Tuesday?


United Therapeutics: Don't Fear The Patent Expiration Too Much

Mar 29, 2025, 8:17 AM EDT - 10 months ago

United Therapeutics: Don't Fear The Patent Expiration Too Much


The Zen Ten - My Top Picks For 2025

Dec 29, 2024, 4:25 PM EST - 1 year ago

The Zen Ten - My Top Picks For 2025

AAPL BBW IBKR INTU META NVDA TSM


cubie
cubie Jan. 14 at 11:40 PM
$LQDA $UTHR when patent ruling, asking for some friends😅
1 · Reply
watchfilingdocuments
watchfilingdocuments Jan. 13 at 11:11 PM
$DDD Updates from Needham Growth Conference, Part 4 of 8: Capable of 3d printing a full human lung. Partnered with all the internal complexity that the body needs. United Therapeutics ($UTHR ) cellularizes it to turn it into a full working lung. In a few years, we'll see humans walking around with a fully 3d printed lung in their body. Webcast: https://wsw.com/webcast/needham148/ddd/2028852
0 · Reply
Outcomes
Outcomes Jan. 13 at 2:06 PM
0 · Reply
Quantumup
Quantumup Jan. 13 at 1:57 PM
BTIG reiterated $LQDA Buy/$49 $UTHR $JNJ $MRK $INSM Here's what BTIG said: https://x.com/Quantumup1/status/2011073992057139619?s=20
0 · Reply
Michaelluh
Michaelluh Jan. 13 at 1:46 PM
$MNKD $UTHR “We have been building up our inventory of Tyvaso inhalers so that we have an adequate supply of drugs and devices to stay on top of literally a hockey stick launch into the IPF indication.” - Martine Rothblatt
0 · Reply
Affizle
Affizle Jan. 12 at 10:45 PM
$MNKD Sounds like $UTHR's CEO is about to neuter Mannkind when it dumps Mannkind's inhaler for their own! Now you know why United has no interest in buying Mannkind! lolz!
2 · Reply
VJLer
VJLer Jan. 12 at 9:52 PM
$DDD $UTHR i wsnt able to here webcast. But i could see the presentation doc.
0 · Reply
VJLer
VJLer Jan. 12 at 9:39 PM
$DDD $UTHR presentation is about to start from JPM. You are able to see a slide on autologous regenerative medicine for creating unlimited supply of transplantable organs.
1 · Reply
clan
clan Jan. 11 at 2:20 AM
$MNKD 2026 for Mannkind Corp. and MNKD will be transfomational; an inflection point. #ItsGrowTime #StockAppreciation $UTHR $SCPH
0 · Reply
clan
clan Jan. 10 at 11:30 PM
$MNKD $UTHR $MRK #inhalablemedications #inhalemyinsulin #afrezza #tyvaso #technosphere #moneymaker #goldengoose
0 · Reply
VJLer
VJLer Jan. 9 at 5:28 PM
$DDD $UTHR https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://www.labiotech.eu/trends-news/3d-printing-lungs/&ved=2ahUKEwiqtIKm_f6RAxWXhYkEHQExO10QFnoECB8QAQ&usg=AOvVaw0Fxjj1sK3xdLf54OQy7owU
0 · Reply
VJLer
VJLer Jan. 9 at 5:17 PM
$DDD $UTHR united therapeutics, 3d's partner in 3d printed lung development presents to the worlds biggest healthcare conference in san fran on mon jan 13 at 1630 eastern. 3d presents at needham in ny on monday at 12:45 eastern
0 · Reply
Quantumup
Quantumup Jan. 9 at 4:09 PM
BTIG reiterated $LQDA Buy/$49 $UTHR $INSM Here's what BTIG said in its note to investors: https://x.com/Quantumup1/status/2009657733755072817?s=20
0 · Reply
clan
clan Jan. 8 at 9:14 PM
$MNKD Yes indeed. Mannkind's fundamentals are continuing to improve. Also $UTHR $SPY
0 · Reply
JFais
JFais Jan. 8 at 7:47 PM
$LQDA (L) Liquidia: Yutrepia's Attributes In Focus, But Binary Risk Shouldn't Be Ignored $UTHR $INSM https://seekingalpha.com/article/4858145?gt=9262607a79e32a4e
0 · Reply
Affizle
Affizle Jan. 7 at 3:06 PM
$MNKD $UTHR will buy out Mannkind only after United's CEO grows his balls back! LOLZ! The only way United would ever consider buying this sad company is if Mannkind gets rid of Affizle like United's CEO got rid of his testes. United does not want the headache of dealing with a failed drug like Affizle. #justfacts #canyoudigit #lolz
1 · Reply
Outcomes
Outcomes Jan. 6 at 5:00 PM
$MNKD $UTHR https://finance.yahoo.com/news/united-therapeutics-corporations-nasdaq-uthr-100644380.html
0 · Reply
Michaelluh
Michaelluh Jan. 6 at 3:44 PM
$MNKD $MNKD $UTHR Just my opinion and my model. Keep in mind this is the economics for the TYVASO DPI IPF portion only. Only thing UTHR is waiting on is Teton 1 confirmation and bridging study alignment with FDA to fully derisk their Crown Jewel 💎. PUTTING OURSELVES IN UTHR / MARTINE’S SHOES — RENT vs BUY TYVASO DPI (IPF) Economics Let’s strip emotion out and do pure capital allocation math. Known facts (non-debatable): • Tyvaso DPI patents/device runway = 20+ years • IPF is orphan + high switching costs • TETON-2 IPF results = best ever recorded • DPI now validated as franchise, not a product This is a multi decade annuity, not a short cycle asset. ⸻ IPF MARKET REALITY • IPF market today: ~$5.5B • Long-term steady state: $10–12B • Post TETON realistic Tyvaso DPI share: ~40% ➡️ Steady-state Tyvaso DPI IPF revenue: ~$4B/year ⸻ CURRENT “RENT” STRUCTURE (UTHR → MNKD) Royalty + manufacturing economics ≈ ~20% leakage At $4B/year IPF revenue: • MNKD gets ≈ $800M/year • UTHR keeps ≈ $3.2B That’s an $800M check every single year. ⸻ 20-YEAR COST OF RENTING • Nominal: $800M × 20 = $16B • Discounted @10%: ~$7B NPV That’s just IPF. Does NOT include: • PAH DPI growth • Manufacturing leverage • Platform value ⸻ NOW THE BUY SCENARIO MNKD buyout math: • $20/share ≈ $6B$25/share ≈ $7.5B For roughly the same NPV as renting IPF alone, UTHR gets: • 100% of Tyvaso DPI economics • Zero royalty leakage — forever • Full DPI platform control • Defensive moat vs BI • Optionality on pipeline ⸻ RENT vs BUY (UTHR VIEW) RENT: • ~$800M/year leakage • ~$7B+ NPV cost • No control • Strategic risk BUY: • One-time ~$6–7.5B • Eliminate leakage permanently • Own franchise for decades • Control platform + future indications Break-even: ~8–9 years Martine doesn’t think in 8-year windows. She thinks in decades. ⸻ BOTTOM LINE From UTHR’s perspective: • Renting Tyvaso DPI is economically irrational long-term • Buying MNKD is NPV-positive and strategically obvious • Every year they wait → MNKD gets more valuable This is not “if” math. It’s when math.
7 · Reply
DrJOS
DrJOS Jan. 6 at 2:49 PM
$DDD $UTHR I want to get usd 50 until 2031
0 · Reply
VJLer
VJLer Jan. 6 at 2:46 PM
$DDD i know it is kind of ridiculous but i think 3D is going to be acquired. There is just so much value there. United therapeutics $UTHR would be my bet. And J P Morgan healthcare conference is next week. Sorry, a bit silly. Oh and they have a market cap of $21.8 billion.
1 · Reply
GreenPhantom
GreenPhantom Jan. 5 at 3:19 AM
$UTHR The company is developing lung transplant technologies and has a unique focus on rare diseases.
0 · Reply
GreenPhantom
GreenPhantom Jan. 5 at 3:17 AM
$UTHR Strong Pipeline: United Therapeutics has several promising drug candidates, including therapies for cystic fibrosis and lung diseases.
0 · Reply